An official website of the United States government
The NISTCHO cell line is a recombinant Chinese hamster ovary cell line engineered to produce cNISTmAb, a monoclonal antibody that recognizes the fusion F glycoprotein on the surface of respiratory syncytial virus (RSV). These cells are invaluable as a standard reference material for developers of therapeutic monoclonal antibodies and serve as an educational resource in biomanufacturing training programs. This study investigates the performance of NISTCHO cells following cryopreservation at temperatures of -80°C and -150°C. Initial cell viability, maximum cell density in culture, and monoclonal antibody production were compared for cells cryopreserved for up to 30 weeks. Cells were thawed and cultured at two-week intervals to monitor their growth behavior, peak cell densities, and antibody production levels. Analysis of cell behavior in culture revealed no significant differences in cell growth or cell production between cells stored at -80°C and those stored at -150°C. These findings affirm that NISTCHO cells can be preserved at -80°C for up to 30 weeks without any adverse effects on their growth or monoclonal antibody production capabilities, an important finding for training and education programs that rely on -80° C freezers to store cell banks.
more »
« less
Assessing the Stability of NISTCHO Cells in Long-Term Culture
NISTCHO is a recombinant Chinese hamster ovary cell line that has been genetically engineered to produce the monoclonal antibody cNISTmAb. This study investigates the stability of the NISTCHO cell line in long-term culture. Low passage number NISTCHO cells from a working cell bank were used to initiate a shake flask culture that was passaged over many weeks, accounting for approximately 129 cell doublings. Cells taken at two-week intervals during this period were used to inoculate fresh cultures, which were monitored over nine days for viable cell concentration, percent viability, and monoclonal antibody production. Results demonstrate consistency among growth curves over time with comparable peak cell densities and cell viabilities. Importantly, cNISTmAb production remained high, with culture titers remaining stable over the culture period and a high number of cell doublings. These findings demonstrate that the NISTCHO cell line has high stability and a sustained capability of producing cNISTmAb over extended culture periods.
more »
« less
- Award ID(s):
- 2055036
- PAR ID:
- 10537892
- Publisher / Repository:
- Zenodo
- Date Published:
- Journal Name:
- Journal of advanced technological education
- ISSN:
- 2832-9627
- Subject(s) / Keyword(s):
- NISTCHO Chinese Hamster Ovary monoclonal antibody stability long-term culture
- Format(s):
- Medium: X
- Right(s):
- Creative Commons Attribution 4.0 International
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Abstract The biomanufacturing industry is advancing toward continuous processes that will involve longer culture durations and older cell ages. These upstream trends may bring unforeseen challenges for downstream purification due to fluctuations in host cell protein (HCP) levels. To understand the extent of HCP expression instability exhibited by Chinese hamster ovary (CHO) cells over these time scales, an industry‐wide consortium collaborated to develop a study to characterize age‐dependent changes in HCP levels across 30, 60, and 90 cell doublings, representing a period of approximately 60 days. A monoclonal antibody (mAb)‐producing cell line with bulk productivity up to 3 g/L in a bioreactor was aged in parallel with its parental CHO‐K1 host. Subsequently, both cell types at each age were cultivated in an automated bioreactor system to generate harvested cell culture fluid (HCCF) for HCP analysis. More than 1500 HCPs were quantified using complementary proteomic techniques, two‐dimensional electrophoresis (2DE) and liquid chromatography coupled with tandem mass spectrometry (LC‐MS/MS). While up to 13% of proteins showed variable expression with age, more changes were observed when comparing between the two cell lines with up to 47% of HCPs differentially expressed. A small subset (50 HCPs) with age‐dependent expression were previously reported to be problematic as high‐risk and/or difficult‐to‐remove impurities; however, the vast majority of these were downregulated with age. Our findings suggest that HCP expression changes over this time scale may not be as dramatic and pose as great of a challenge to downstream processing as originally expected but that monitoring of variably expressed problematic HCPs remains critical.more » « less
-
Abstract The Chinese hamster ovary (CHO) cell lines that are used to produce commercial quantities of therapeutic proteins commonly exhibit a decrease in productivity over time in culture, a phenomenon termed production instability. Random integration of the transgenes encoding the protein of interest into locations in the CHO genome that are vulnerable to genetic and epigenetic instability often causes production instability through copy number loss and silencing of expression. Several recent publications have shown that these cell line development challenges can be overcome by using site‐specific integration (SSI) technology to insert the transgenes at genomic loci, often called “hotspots,” that are transcriptionally permissive and have enhanced stability relative to the rest of the genome. However, extensive characterization of the CHO epigenome is needed to identify hotspots that maintain their desirable epigenetic properties in an industrial bioprocess environment and maximize transcription from a single integrated transgene copy. To this end, the epigenomes and transcriptomes of two distantly related cell lines, an industrially relevant monoclonal antibody‐producing cell line and its parental CHO‐K1 host, were characterized using high throughput chromosome conformation capture and RNAseq to analyze changes in the epigenome that occur during cell line development and associated changes in system‐wide gene expression. In total, 10.9% of the CHO genome contained transcriptionally permissive three‐dimensional chromatin structures with enhanced genetic and epigenetic stability relative to the rest of the genome. These safe harbor regions also showed good agreement with published CHO epigenome data, demonstrating that this method was suitable for finding genomic regions with epigenetic markers of active and stable gene expression. These regions significantly reduce the genomic search space when looking for CHO hotspots with widespread applicability and can guide future studies with the goal of maximizing the potential of SSI technology in industrial production CHO cell lines.more » « less
-
AbstractThe pharmaceutical industry employs various strategies to improve cell productivity. These strategies include process intensification, culture media improvement, clonal selection, media supplementation and genetic engineering of cells. However, improved cell productivity has inherent risk of impacting product quality attributes (PQA). PQAs may affect the products’ efficacy via stability, bioavailability, or in vivo bioactivity. Variations in manufacturing process may introduce heterogeneity in the products by altering the type and extent of N-glycosylation, which is a PQA of therapeutic proteins. We investigated the effect of different cell densities representing increasing process intensification in a perfusion cell culture on the production of an IgG1-κ monoclonal antibody from a CHO-K1 cell line. This antibody is glycosylated both on light chain and heavy chain. Our results showed that the contents of glycosylation of IgG1-κ mAb increased in G0F and fucosylated type glycans as a group, whereas sialylated type glycans decreased, for the mAb whole protein. Overall, significant differences were observed in amounts of G0F, G1F, G0, G2FS1, and G2FS2 type glycans across all process intensification levels. G2FS2 and G2 type N-glycans were predominantly quantifiable from light chain rather than heavy chain. It may be concluded that there is a potential impact to product quality attributes of therapeutic proteins during process intensification via perfusion cell culture that needs to be assessed. Since during perfusion cell culture the product is collected throughout the duration of the process, lot allocation needs careful attention to process parameters, as PQAs are affected by the critical process parameters (CPPs). Key points• Molecular integrity may suffer with increasing process intensity.• Galactosylated and sialylated N-glycans may decrease.• Perfusion culture appears to maintain protein charge structure.more » « less
-
null (Ed.)There is renewed interest in the possibility of using precipitation for initial capture of high-value therapeutic proteins as part of an integrated continuous downstream process. Precipitation is greatly facilitated by the high product titers now achieved in most cell culture processes, in sharp contrast to chromatographic processes whose performance is reduced at high titers. The current study used a combination of reversible cross-linking (zinc chloride, ZnCl2) and volume exclusion (polyethylene glycol) agents to precipitate a monoclonal antibody product directly from harvested cell culture fluid using a continuous tubular precipitation reactor. The precipitates were then dewatered and continuously washed using tangential flow filtration, with a countercurrent-staged configuration used to reduce the amount of wash buffer required and increase host cell protein removal. Long-term operation was achieved by operating the membrane modules below the critical filtrate flux to avoid fouling. Experimental results demonstrate the feasibility of this fully continuous integrated precipitation process at bench scale, with design calculations used to explore the key factors affecting the performance of this system for initial antibody capture.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- https://doi.org/10.5281/zenodo.13546665
